JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 23 No. 3 235-240
© 1982 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Echenique, R. L.
Right arrow Articles by Hill, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Echenique, R. L.
Right arrow Articles by Hill, C. S.

Critical Evaluation of Serum Thyroglobulin Levels and I-131 Scans in Post-Therapy Patients with Differentiated Thyroid Carcinoma: Concise Communication

Raul L. Echenique, Leela Kasi, Thomas P. Haynie, Howard J. Glenn, Naguib A. Samaan and C. Stratton Hill

The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas

Correspondence: For reprints contact: Raul L. Echenique, MD, P.O. Box 36734, Houston, TX 77036.

ABSTRACT

Serum thyroglobulin measurements by radioimmunoassay were performed in the follow-up of 68 patients with differentiated thyroid carcinoma undergoing I-131 total-body scans following surgery and/or I-131 therapy. Of 12 patients with distant metastases demonstrated by I-131 scan, thyroglobulin levels were elevated (>60 ng/ml) in nine (75%); the remaining 25% either ranged between 20 and 60 ng/ml or were below 20 ng/ml in spite of having functional metastases. Of six patients with only regional lymph-node metastases demonstrated by I-131 scan, only one (16%) had an elevated thyroglobulin level, while two fell in the 20–60 ng/ml range and three were below 20 ng/ml. Of the remaining patients with no metastatic disease demonstrable by I-131 scan, three (6%) had elevated thyroglobulin levels. These patients were subsequently found to have metastatic disease by other criteria. These results suggest caution in the use of thyroglobulin levels as a replacement for I-131 scans in the follow-up of differentiated thyroid carcinoma. Based on our study, however, the two methods complement each other to achieve maximum sensitivity and reliability.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1982 by the Society of Nuclear Medicine.